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Summary Objectives: To determine risk factors for GBS colonisation in Gambian mothers
and in their infants from birth to day 60e89 of age.
Methods: Swabs and breastmilk from mothers/infant pairs were collected and cultured on se-
lective agar. Negative samples were analysed for GBS DNA via real-time PCR. Positive isolates
were serotyped using multiplex PCR and gel-agarose electrophoresis.
Results: Seven hundred and fifty women/infant pairs were recruited. 253 women (33.7%) were
GBS-colonised at delivery. The predominant serotypes were: V (55%), II (16%), III (10%), Ia
(8%) and Ib (8%). 186 infants were colonised (24.8%) at birth, 181 (24.1%) at 6 days and 96 at
day 60e89 (14%). Infants born before 34 weeks of gestation and to women with rectovaginal
and breastmilk colonisation at delivery had increased odds of GBS colonisation at birth. Season
of birth was associated with increased odds of persistent infant GBS colonisation (dry season
vs. wet season AOR 2.9; 95% CI 1.6e5.2).
Conclusion: GBS colonisation is common in Gambian women at delivery and in their in-
fants to day 6089 and is dominated by serotype V. In addition to maternal
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colonisation, breastmilk and season of birth are important risk factors for infant GBS
colonisation.
Crown Copyright ª 2015 Published by Elsevier Ltd on behalf of The British Infection
Association. This is an open access article under the CC BY license (http://
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Introduction
Group B Streptococcus (GBS) is a leading cause of neonatal
infection worldwide and transmission occurs mainly from
mother to child during the peripartum period.1 In the Afri-
can setting, information on GBS disease prevalence remains
sparse.2 Under-identification and under-reporting of GBS
cases and deaths appear likely, especially where it is diffi-
cult to access healthcare. Maternal colonisation is the lead-
ing risk factor for both early and late onset GBS disease,1
yet in resource-poor countries little is known about
maternal colonisation rates. Little is also known about
maternal or infant colonising serotypes in African countries
but reports indicate that serotype (ST) V may be important
as both a colonising and invasive disease serotype,3,4 as it
was in the USA in the 1990s.5
The current leading candidate for maternal vaccination
is a trivalent capsular polysaccharide protein conjugate
vaccine containing ST Ia, Ib and III which is based on data on
invasive disease serotypes in the USA, UK6 and South Af-
rica.3 Here, we report the results of a longitudinal prospec-
tive cohort study to investigate the prevalence of colonising
and invasive disease serotypes of Gambian women and their
infants from delivery to three months of age.
Methods
Study design and participants
We undertook a prospective longitudinal cohort study in
two government health centres offering antenatal care to
women in the Fajara area of costal Gambia, a low-income
country with an annual birth rate of 43.1/1000 population,
neonatal sepsis rate of 4.42/1000 live births7 and neonatal
mortality rate of 28/1000 live births.8 The combined birth
rate of these two health centres is approximately 12,500
births annually. The health centres were selected to be
representative of the level of care usually available to
Gambian women.
The eligibility criteria for maternal participation in the
study included all pregnant women over the age of 18 years
who had a negative HIV test and were deemed to be at low
risk for pregnancy complications (no evidence of pre-
eclampsia, cardiomyopathy, maternal gestational diabetes,
placenta praevia, twin pregnancy). Women were invited to
deliver at the health centre and offered a confirmatory HIV
test prior to enrolment. Women found to be HIV positive
were referred for specialist ongoing care. Mothers were
excluded if they were not planning to breastfeed or were
unable to remain in the Fajara area for the first three
months postpartum. Healthy infants over 32 weeks of
gestation assessed using the Ballard score and weighing
over 2.5 kg were included. Infants were excluded if they
had obvious congenital abnormalities or required resusci-
tation at the time of delivery requiring transfer to a
neonatal unit. Mother and infant pairs were recruited to
the study between 1st January 2014 and 31st December
2014 if both mother and infant met the inclusion criteria.
All eligible women and infants were recruited until the pre-
defined sample size was reached. Participants were fol-
lowed up daily at home until day 6 and then asked to return
to clinic when the infant 6089 days old for final follow up
visit and vaccinations. If an infant died during the study a
verbal autopsy was carried out to assess the potential cause
of death.
Ethics statement
Field workers explained the purpose of the study to eligible
participants in their local language (Mandinka, Wolof, Fula,
Jolla, Mangago) and each participant signed an informed
consent form, or in case of illiteracy, thumb-printed and
the consent form was signed by an impartial witness. The
study was approved by the joint Gambian Government/
Medical Research Council Research Ethics Committee, SCC
1350 V4.
Procedures
Sampling
Rectovaginal swabs were taken from enrolled women
presenting in labour to one of the health centres and cord
blood was taken after delivery but prior to separation of
the placenta. A screening questionnaire was completed
after four hours postpartum and the infant checked for any
abnormalities requiring medical intervention. The ques-
tions included ethnic origin, gravida, parity, maternal
weight, blood pressure, haemoglobin concentration, use
of medication/traditional medicines/antibiotics and vacci-
nation in pregnancy, any illnesses in pregnancy, number of
antenatal attendances, HIV status, education, diet, com-
pound location and presence of cattle at the compound.
Nasopharyngeal and rectal swabs were taken from all
eligible infants at four hours after birth. Mothers were
provided with soap and asked to wash their hands and wipe
their breasts with alcohol wipes before hand expressing
colostrum/milk within the first 12 h after birth, at day 6 and
between days 60 and 89. Nasopharyngeal and rectal swabs
were also taken from infants at day 6 of life and again at
60e89 days of life. Infants who were unwell before day 6
were assessed at home and referred for treatment as
necessary. All sick infants had a blood culture taken on
admission to hospital. At each visit a standardized ques-
tionnaire was completed in the local language documenting
infant anthropometry, feeding, vaccinations, signs and
symptoms of infant illnesses, use of antibiotic/traditional
medicine and vital signs.
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Laboratory procedures
Copan (for rectal and rectovaginal samples) and Dacron (for
nasopharyngeal samples) swabs were collected in skim-milk
tryptone glucose glycerol (STGG) transport medium, stored
at 4 C and transported to the Medical Research Council
laboratories, The Gambia within 4 h of collection. On
arrival the samples were vortexed briefly and immediately
frozen at 70 C until processing.
All swab specimens were inoculated into ToddeHewitt
broth supplemented with colistin and nalidixic acid and
were processed for isolation of GBS using standard labora-
tory procedures.1 Presumptive positive GBS samples were
identified by latex agglutination (Oxoid). Five colonies
from positive samples were harvested into phosphate buff-
ered saline (PBS) and subjected to real-time polymerase
chain reaction (PCR).9 Negative samples were also sub-
jected to confirmation by real-time PCR. All GBS positive
isolates were then serotyped using conventional PCR and
identified using gel PCR and agarose electrophoresis.10
Outcomes
The primary outcome was prevalence of ST-specific GBS
colonisation in mothers and infants at birth, six days and
between days 60e89 using microbiological culture and
molecular techniques. Secondary outcomes were detection
of GBS in breastmilk; infant acquisition and loss of GBS
colonisation during the study follow up period and infant
GBS disease (sample obtained from sterile site), as ascer-
tained by positive microbiological culture and confirmatory
PCR. Swabs were considered negative if no GBS was evident
by culture and PCR and positive if GBS was found on culture
and PCR. If swabs were negative on culture but positive on
PCR, conventional PCR was performed to determine sero-
type. If the second PCR resulted in the identification of a
GBS serotype the samples were deemed positive. If no
serotype was identified or the DNA did not amplify, samples
were deemed negative.
Statistical analysis
Calculated on the basis of the previously observed 24%
colonisation rate,11 the intended sample size was 750
mothers, to provide at least 180 colonised women for sero-
type analysis (95% confidence interval (CI) 150e202 women)
and 90 colonised infants (95% CI 72e107 infants). The sam-
ple size of 180 colonised women was chosen to ensure at
least 10 samples of the least prevalent ST based on histor-
ical data from The Gambia (ST III (6%)),11 in order to allow
longitudinal colonisation analysis.
Statistical analyses were completed using STATA version
12 (StataCorp 2013, Texas) and GraphPad Prism version 6.0
(GraphPad Software Inc, La Jolla, California). Descriptive
statistics included the prevalence of colonisation at indi-
vidual time points expressed as a proportion of the total
number of participants. Odds ratios and 95% confidence
intervals (CI) were calculated to determine risk of maternal
and infant colonisation at birth in a single variable analysis.
Adjusted odds ratios were then calculated using any vari-
ables from the single variable analysis with a p-value <0.2
using a backwards-stepwise procedure.
Analyses of the changes in infant colonisation over time
were undertaken using longitudinal logistical regression.
Adjusted odds ratios were then calculated using any
variables from the single variable analysis with a p-value
<0.2 using a backwards-stepwise procedure. New acquisi-
tion of GBS was defined as detection of a new serotype by
culture or PCR that was not previously present. Clearance
of colonisation was defined as a negative GBS culture or
PCR for a specific serotype following a positive sample at
the previous visit for the same ST. The log-rank test was
used to examine differences in duration of colonisation
between serotypes. Using an expected vertical transmission
rate of 50%1 we calculated observed vs. expected statistics
for risk of infant colonisation by ST. For comparison be-
tween our study and the study conducted in 1994, we calcu-
lated 95% confidence intervals for both studies. P-values
<0.05 were considered significant.
Role of the funding source
The funders had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
All authors had full access to all the data and the
corresponding author had final responsibility for the deci-
sion to submit for publication.
Results
Demographics
Between 15th January 2014 and 31st January 2015 we
recruited a total of 750 mothers and their infants to the
study. All mothers met the inclusion criteria except one,
who was admitted to hospital on day three post-partum
severely unwell and subsequently tested positive for HIV1,
despite a negative test at 20 weeks of gestation. She and
her infant were referred for further management and
samples excluded from further analysis. Of the remaining
eligible women and infants, 722 completed the day 6 visit
(median age at follow up 8 days, IQR 7e9) and 684
completed 60e89 days follow up (median age at follow up
62 days, IQR 60e63). The main reasons for not completing
follow up were: 31 women moved out of area, 20 women
whose partners were not in agreement with continued
study participation, one maternal HIV, nine infant deaths,
five declined for other reasons. Participant flow diagram
and demographic characteristics of mothereinfant pairs
are outlined in Supplementary Fig. 1.
Antibiotic treatment
Over the course of the study, 77 women received antimicro-
bials during pregnancy: 34 for urinary tract infection; 10 for
pneumonia; 14 for vaginal discharge; 9 for malaria and 10 for
non-malarial fever. Of these, 73 women received amoxicillin
(median time prior to delivery 42 days [IQR 18e63 days]); 16
received antimalarial therapy (median 38 [31e41]) and three
received erythromycin. In the three months of follow up, 51
infants required antibiotic therapy: 34 received ampicillin
and gentamicin for presumed neonatal sepsis (median 18
days old [IQR 4e34]); 10 received amoxicillin or cloxacillin
for skin infections (20 days [10e58]); 7 received other
antibiotics (18 days [11e23]). Antibiotic therapy was
included in adjusted analyses and had no impact on
colonisation of mother or infant at any time point.
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Table 1 Mother and infant demographics and odds ratios for maternal GBS colonisation at delivery.
Total Colonised Non-colonised p-value OR (95% CI)
Maternal
age yrs
<20 110 40 70 0.78 1
20e24 262 81 181 0.78 (0.5e1.3)
Mean: 25
(IQR 18e41)
25e29 203 71 132 0.94 (0.6e1.5)
30þ 175 61 114 0.99 (0.6e1.7)
Ethnicity Mandinka 315 115 200 0.38 1
Wolof 108 36 72 0.9 (0.5e1.4)
Fula 126 45 81 1 (0.6e1.5)
Jola 118 33 85 0.7 (0.4e1.0)
Other 81 23 58 0.7 (0.4e1.2)
Missing 2 1 1
Maternal
weight (kg)
<50 27 7 20 0.03* 1
50e70 424 128 296 1.2 (0.5e3.0)
70e90 148 61 87 2.0 (0.8e5.0)
>90 145 56 91 1.8 (0.7e4.4)
Missing 6 3 3
Maternal illness
in pregnancy
Yes 128 45 83 0.32 1
No 504 165 339 1.1 (0.7e1.7)
Missing 118 43 75
Maternal Hb below
10 g/dL
No 99 42 57 0.04* 1
Yes 651 211 440 0.5 (0.3e0.9)
Maternal antibiotics
in pregnancy
No 505 166 339 0.74 1
Yes 128 44 84 1.1 (0.7e1.6)
Missing 117 74 43
Gravida 1 208 67 141 0.44 1
Median: 2 (IQR 1e4) 2e4 370 121 249 1 (0.7e1.5)
5þ 169 63 116 1.3 (0.8e2.0)
Missing 3 1 2
Parity 0e1 212 68 144 0.59 1
Median: 1 (IQR 0e4) 2e4 468 164 304 1.1 (0.8e1.6)
5þ 67 20 47 1.1 (0.7e1.7)
Missing 3 1 2
Living children 0 230 80 150 0.17 1
Median: 1 (IQR 0e3) 1e4 465 155 311 0.9 (0.7e1.3)
5þ 53 17 36 0.9 (0.5e1.7)
Missing 2 2 0
Spontaneous abortion 0 649 213 436 0.09 1
Median 1(IQR 0e2) 1 53 20 33 1.2 (0.7e2.2)
2þ 14 7 7 1.5 (0.8e2.7)
Missing 34 16 18
Stillbirths 0 641 207 434 0.05** 1
1 75 29 46 0.9 (0.4e2.1)
2þ 28 15 13 3.6 (1.2e10.5)
Missing 6 2 4
Number of ANC visits 1 303 85 218 0.01* 1
2þ 447 168 279 1.5 (1.1e2.1)
Attendance by midwife
or TBA
Midwife 436 168 268 0.001* 1
TBA 254 67 187 0.5 (0.4e0.8)
Missing 60 37 23
Birth season Dry cool 280 55 225 0.000* 1
Dry hot 175 85 90 3.9 (2.5e5.9)
Wet 295 113 18 2.5 (1.7e3.7)
Infant sex Male 369 122 247 0.59 1.1 (0.8e1.5)
Female 381 131 250
Birth
weight (kg)
2.5e3 260 73 187 0.04* 1
3.1e4 464 169 295 1.5 (1.1e2.0)
>4.0 26 11 15 1.9 (0.8e4.3)
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Prevalence and risk factors for maternal
colonisation
The overall prevalence of recto-vaginal GBS colonisation at
delivery was 33.7% (253 women). In single variable analysis
maternal weight >50 kg, maternal haemoglobin <10 g/dL,
more than one previous stillbirth, more than one antenatal
clinic visit, midwife delivery, giving birth during the dry hot
or wet seasons, birth weight over 3 kg and gestation under
34 weeks were associated with increased risk of GBS
colonisation (Table 1). In adjusted analysis, maternal hae-
moglobin <10 g/dL, history of more than one previous still-
birth, attendance at delivery by a midwife rather than a
trained birth attendant and giving birth during the wet or
dry hot season were associated with increased odds of
maternal GBS colonisation at delivery (Table 2).
GBS colonisation dynamics at birth
There were 253 colonised mothers and 186 colonised
infants at birth, of whom 146 were born to colonised
women (57.7%). Table 3 describes the number of colonised
infants at birth, day 6 and at 6089 days of age according
to colonisation site. Fig. 1a and b demonstrate colonisation
dynamics at each time point.
Compared to mother/infant pairs who were not colon-
ised at birth, mother/infant pairs were more likely to both
be colonised if mother’s weight was below 50 kg, infant was
born at less than 37 weeks of gestation, born during the dry
hot or wet seasons, mothers with more than one previous
stillbirth, mothers attending antenatal clinic more than
once, infants delivered by midwives, infants born with a
birth weight below 3.3 kg or receiving breastmilk colonised
with GBS (Table 4).
In adjusted analysis, compared to mother/infant pairs
who were not colonised at birth, mother/infant pairs were
more likely to both be colonised if birth occurred in the dry
hot or wet seasons, mothers with one or more previous
stillbirths or spontaneous abortions, infants born before 34
weeks of gestation. Compared to mother/infant pairs where
neither was colonised, mother/infant pairs where the
mother was colonised but not the infant were more likely if
the mother had more than one previous stillbirth, or if the
mother gave birth during the wet season. Infant colonisation
in the absence of maternal colonisation (n Z 40) was
associated with gestation before 34 weeks (Table 5).
Most notably, compared to mother/infant pairs at birth
where neither were colonised, infants born to mothers who
had GBS cultured in their breastmilk were more likely to be
colonised with GBS (Table 5).
GBS colonisation dynamics at birth, day 6e9 and
day 60e89
Infants born to colonised mothers had an increased risk of
colonisation at birth and day 6e9 if born during the dry hot
season or if born before 34 weeks of gestation. For all
variables the risk of colonisation decreased over time
(Table 6).
Infants born to non-colonised mothers had an increased
risk of being GBS colonised on day 6e9 and at day 60e89 if
born during the wet season. At birth infants were more
likely to be colonised if breastmilk was colonised and they
remained more likely to be colonised at both 6e9 days and
day 60e89.
Serotype distribution
The predominant maternal rectovaginal colonising serotype
was ST V in 54.9% of colonised mothers. Mothers’ breastmilk
was more likely to be colonised with ST V (p < 0.001) at all
time points than any other serotype. Infants were more
likely to be colonised with ST V at birth (p Z 0.004), day
6e9 (pZ 0.004) and day 60e89 (pZ 0.009) than any other
serotypes. At birth, infants were more likely to be colonised
with ST III and V if their mothers were colonised with ST III
and V (x2 Z 24.4, p < 0.001) compared to mothers colon-
ised with other serotypes. Fig. 2 outlines the percentage
of different serotypes at different time points in infants
and in breastmilk.
Table 1 (continued )
Total Colonised Non-colonised p-value OR (95% CI)
Gest. age at
birth (wks.)
<34 56 18 38 0.03* 1
34e37 231 83 148 0.7 (0.4e1.1)
38þ 463 152 311 1.1 (0.7e1.7)
IQR Z inter-quartile range; ANC Z antenatal clinic; TBA Z trained birth attendant. * p-values <0.05 were considered significant.
** p-value Z 0.0475.
Table 2 Multivariable analysis: maternal GBS colonisation
at time of delivery.
AOR (95% CI) p-value
Maternal
weight (kg)
<50 1
50e70 1.0 (0.4e1.6) 0.96
70e90 1.7 (0.6e4.5) 0.30
>90 1.4 (0.3e4.7) 0.68
Number of
ANC visits
1 1
2þ 1.3 (0.9e1.8) 0.16
Maternal Hb below
10 g/dL
No 1
Yes 0.7 (0.4e0.9) 0.04*
Attendance by
midwife or TBA
Midwife 1
TBA 0.6 (0.4e0.9) 0.03*
Previous stillbirths 0 1
1 0.9 (0.4e2.0) 0.86
2þ 5.4 (1.6e18.0) 0.009*
Birth season Dry cool 1
Dry hot 2.0 (1.3e3.1) 0.004*
Wet 1.8 (1.2e2.7) 0.008*
ANC Z antenatal clinic, Hb Z haemoglobin; TBA Z trained
birth attendant. * p-values <0.05 were considered significant.
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Neonatal sepsis
During the study period, 51 infants (6.8%) presented with
signs of infection (68 per 1000 live births): 18 with signs of
pneumonia, 22 with signs of other febrile illness, ten with
skin infections and one with signs of meningitis. One child
presenting on day 6 of life with irritability and poor
feeding, had a positive CSF culture for GBS and was treated
for 21 days with ampicillin and gentamicin (invasive GBS
disease incidence: 1.3 per 1000 live births). This infant was
born to a mother who had ST V cultured from both
rectovaginal swab and breastmilk at birth and day 6 of
life and the infant swab was also positive at birth and day 6
for ST V. The CSF sample was not typed due to laboratory
constraints.
Nine infants died during the study period. Based on
verbal autopsy, six deaths were due to pneumonia (median
age at death 7 days [IQR 2e35]); three due to sepsis
(median age 6 days [1e48]). Blood cultures were negative
in all cases. One infant was born to a colonised mother and
was also colonised with GBS at the time of birth but was not
colonised on day 6. This infant died of presumed sepsis on
day 48 of life. No other infants who died or their mothers
were colonised with GBS at time of birth or day 6 of life. All
infants died prior to the final follow-up appointment. It is
therefore, not possible to determine whether any of these
deaths were due to GBS disease.
Discussion
In this first colonisation study of Gambian mothers and their
infants for 25 years and the first longitudinal study under-
taken in this population, we demonstrate high prevalence
of GBS colonisation in mothers at birth and in their infants
up to 90 days of life. In addition, we demonstrate that
infants were more likely to be colonised if GBS was isolated
from their mother’s breastmilk. The overall prevalence of
maternal GBS in our population is higher than in the original
Table 3 Dynamics of colonisation by site and time point.
Birth n Z 750; 253 colonised mothers (% total)
Mother and infant colonised 146 (19.5% total; 57.7% born to colonised mothers)
Infants colonised, mothers not colonised 40 (5.3)
Total colonised infants 186 (24.8)
Mothers colonised, infants not colonised 107 (14.3)
Neither mother nor infant colonised 457 (60.9)
Site of colonisation at birth (% colonised infants)
Nasopharyngeal and rectal 96 (51.6)
Rectal only 68. (36.6)
Nasopharyngeal only 22 (11.8)
Site of colonisation day 6e9; n Z 722 (% of the 181 colonised infants)
Infant rectal colonisation only 95 (52.5)
Infant nasopharyngeal colonisation only 29 (16.0)
Infant nasopharyngeal and rectal 57 (31.5)
Site of colonisation day 60e89; n Z 684 (% the 94 colonised infants)
Infant rectal colonisation only 57 (60.6)
Infant nasopharyngeal colonisation only 26 (27.7)
Infant nasopharyngeal and rectal 11 (11.7)
Figure 1 a e infant GBS colonisation status over time. Bars
represent percentage of infants colonised at each of the time
p o i n t s ; b l a c k b a r Z b i r t h , g r e y Z d a y 6 a n d
patterned Z three months. b e breastmilk colonisation over
time. Bars represent percentage of infants colonised at each
of the time points; black bar Z birth, grey Z day 6 and
patterned Z three months.
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study by Suara et al. (1992) (Suara 22% colonised (95% CI
15.04e28.96) vs. present study 33.7% colonised
(29.63e36.37); p Z 0.007).11 However, the previous study
likely under-identified GBS colonisation as selective me-
dium was not used. An additional feature that may account
for a lower colonisation rate was the collection of vaginal
but not rectal swabs, which are known to have a higher
yield for GBS.12 The prevalence of GBS colonisation in our
study is similar to the reported pooled prevalence in South
African women (30.4%).3
Our finding that mothers with more than one stillbirth
demonstrated an increased odds of having a colonised
infant are in concordance with Monari et al., who identified
stillbirth as a risk factor for invasive EOGBS disease.13 This
phenomenon has also been noted in non-human primates,14
but there are currently little human data on the association
between stillbirth, GBS colonisation and invasive disease.
Table 4 Characteristics of mother infant pairs according
to colonisation status at birth.
Total MþIþ MþI MIþ MI p-value
Maternal
age
0.96
<20 110 23 17 2 68
20e24 262 43 38 19 162
25e29 203 46 25 11 121
30þ 175 34 27 8 106
Ethnicity 0.10
Mandinka 315 63 52 23 177
Wolof 108 23 13 8 64
Fula 126 28 17 2 79
Jola 118 21 12 3 82
Other 81 11 12 4 54
Missing 2 0 1 0 1
Maternal
weight (kg)
0.04*
<50 27 2 5 4 16
50e70 424 74 54 21 275
70e90 148 36 25 3 84
90þ 145 32 23 9 81
Missing 6 3 0 3 0
Mother ill 0.48
Yes 128 24 21 3 80
No 504 97 68 25 314
Missing 118 25 18 12 63
Maternal Hb
<10 g/dL
0.11
No 99 24 18 2 55
Yes 651 122 89 33 403
Maternal
antibiotics
in
pregnancy
No 505 99 92 0 314 0.91
Yes 128 23 24 0 81
Gravida 0.44
1 208 39 28 13 128
2e4 370 67 54 17 232
5þ 169 39 25 10 95
Missing 3 1 0 0 2
Parity 0.94
0e1 212 39 29 13 131
2e4 468 96 68 24 280
5þ 67 10 10 3 44
Missing 3 1 0 0 2
Living
children
0.66
0 230 43 37 14 136
1e4 465 94 61 25 285
5þ 53 7 9 1 36
Missing 2 2 0 0 0
Spontaneous
abortion
0.09
0 649 121 92 31 405
1 53 14 6 4 29
2þ 14 7 1 0 6
Missing 34 11 0 5 18
Table 4 (continued )
Total MþIþ MþI MIþ MI p-value
Stillbirths 0.03*
0 641 119 87 32 403
1 75 20 9 6 40
2þ 28 5 10 2 11
Missing 6 2 1 0 3
Number of
ANC visits
0.002*
1 303 58 27 15 203
2þ 447 88 80 25 254
Midwife
delivery
436 108 60 20 248 <0.001*
TBA 254 29 38 12 175
Missing 60 9 9 8 34
Infant sex 0.71
Male 369 72 50 23 224
Female 381 74 57 17 233
Season <0.001*
Dry cool 280 22 33 17 208
Dry hot 175 66 19 3 87
Wet 295 58 55 20 162
Birth
weight (kg)
0.02*
2.5e3 260 44 29 20 167
3.1e4 464 95 74 18 277
>4.0 26 7 4 2 13
Gestation
(weeks)
0.04*
<34 56 13 5 4 34
34e37 231 57 26 12 136
38þ 463 76 76 24 287
Breastmilk
colonised
<0.001*
Yes 64 31 18 7 8
No 600 101 77 31 391
Missing 86 14 12 2 58
MþIþ Z mother and infant colonised; MþI Z mother colon-
ised, infant not colonised; MIþ Z mother not colonised, in-
fant colonised, MI Z neither mother nor infant colonised;
TBA Z trained birth attendant; ANC Z antenatal clinic.
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This finding could be important in reducing adverse preg-
nancy outcomes especially following introduction of any
new vaccine.
The prevalence of infant colonisation in our study is
similar to previous studies in Europe15e18 but higher than
those from other most African countries,19 probably due
to the differences in microbiological methods. To our
knowledge this is the first longitudinal study of infant colo-
nisation and demonstrates that GBS colonisation rates
remain high up to three months of life. We demonstrate
that the overwhelming risk factor for infant colonisation
at all time points was having a mother who was GBS colon-
ised at the time of birth. We also established that delivery
before 34 weeks of gestation increased the odds of GBS
colonisation at birth. Similar studies have indicated that
risk factors for infant colonisation include maternal recto-
vaginal colonisation, preterm delivery, low birth weight
and maternal urinary tract infection.1,15,18,20 However, un-
like these studies we did not identify low birth weight as a
risk factor, probably because we only recruited infants
weighing more than 2.5 kg.
Several case reports suggest that isolation of GBS in
breastmilk is implicated in late onset GBS disease.21,22 Our
data suggest that GBS colonisation in breastmilk is a risk
factor for neonatal colonisation, both at delivery and for
persistence of infant colonisation throughout the first three
months of life. This is an important finding in a population
such as this with high rates of breast-feeding. The mecha-
nism for this is not clear; it is possible that GBS enters
the mammary glands following suckling from a colonised in-
fant, although there is also evidence that normal gut micro-
biota may pass into the breast via the entero-mammary
circulation.23 Whether it is also a risk factor for late onset
disease in this population is not known. Conversely, it might
conceivably be a protective factor through induction of im-
munity.24 The relevance of this finding requires further
study.
It is interesting to note that risk factors for maternal
colonisation include midwife delivery and increasing number
of antenatal visits. This phenomenon has not been previ-
ously noted in resource-poor settings where hygienic birth
practices may be compromised. GBS has been implicated in
nosocomial outbreaks in several hospitals globally,25,26
although the number of reported outbreaks in resource-
rich countries has greatly reduced since the implementation
of GBS screening programmes. It is conceivable that unclean
birth practices, especially in times of clean water shortage,
such as the dry hot season or during the wet season may
Table 5 Multivariable analysis of maternal/infant pairs by GBS colonisation status at time of delivery.a
MþIþ
OR (95% CI)
MþI
OR (95% CI)
MIþ
OR (95% CI)
Season
Dry cool 1 1 1
Dry hot 8.3 (3.9e17.6) 1.8 (0.8e3.9) 0.4 (0.1e1.4)
Wet 3.5 (1.8e6.8) 2.3 (1.3e4.3) 1.1 (0.5e2.5)
Breastmilk colonised
Yes 21.0 (8.6e51.3) 11.5 (4.5e29.4) 7.5 (2.0e27.5)
No 1 1 1
Gestation (weeks)
<34 1 1 1
34e37 0.9 (0.9e1.0) 1.0 (0.9e1.1) 0.9 (0.8e1.0)
38þ 0.4 (0.2e1.0) 0.5 (0.3e1.6) 0.9 (0.8e1.0)
Midwife delivery 1 1 1
TBA 0.9 (0.5e1.6) 1.0 (0.6e1.8) 0.6 (0.2e1.3)
Number of antenatal clinic visits
1 1 1 1
2þ 1.1 (0.7e1.9) 1.2 (0.8e2.1) 1.3 (0.6e2.8)
Stillbirths
0 1 1 1
1 2.5 (1.0e8.7) 2.0 (1.0e4.7) 1.4 (0.3e5.9)
2þ 2.4 (0.9e4.1) 2.2 (0.9e2.1) ND
Spontaneous abortion
0 1 1 1
1 0.9 (0.5e1.4) 0.8 (0.3e2.1) 1.0 (0.2e5.5)
2þ 1.2 (1.1e2.3) 0.3 (0.0e2.2) 2.0 ND
Gravida
1 1 1 1
2e4 1.0 (0.9e1.0) 1.1 (0.6e2.0) 1.0 (0.8e1.2)
5þ 1.0 (0.5e2.0) 0.8 (0.4e1.8) 0.8 (0.3e2.3)
MþIþZ mother and infant colonised; MþIZ mother colonised, infant not colonised; MIþZ mother not colonised, infant colonised,
MI Z neither mother nor infant colonised. 1 Z adjusted odds ratios are compared to this group; TBA Z trained birth attendant.
a MI Z base group.
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facilitate the fecal-oral spread of GBS between colonised
and non-colonised mothers and their infants.
A large proportion of women were colonised with ST V,
similar to the previous smaller study by Suara et al., which
identified 32 colonised pregnant women of whom 12 (30%)
were colonised with ST V.11 ST V has been identified as an
important neonatal and adult colonising and disease
causing serotype globally.3,27,28 Additionally, in our cohort,
ST V was the predominant serotype cultured in breastmilk
and ST Ib and V were associated with longer median coloni-
sation duration compared to other serotypes. A study of
pregnant women from South Africa found a high prevalence
of GBS colonisation throughout pregnancy, with ST V and ST
III colonisation lasting longer than other serotypes (ST V
mean duration 8.6 weeks; 95% CI 6.8e10.4 vs. ST III 9.2
weeks; 95% CI 8.1e10.2).3 The difference in serotype distri-
bution and duration of colonisation between these studies
may be due to population differences between South Africa
and the Gambia. There are no other longitudinal infant
colonisation studies with which to compare our results.
Our results may also indicate differences in maternally
derived antibody that might prevent colonisation of certain
serotypes in these diverse populations. In the most recent
study from South Africa, the authors demonstrate that it
is the acquisition of a new serotype that is associated
with EOS rather than the persistent serotype, probably
due to the absence of maternal antibody to this new
serotype.29
Our study has several limitations. First, our results are
limited by the sensitivity of detection of GBS on selective
media, estimated at 85%30 and by the fact that we identi-
fied the serotype by conventional PCR. This may imply that
we have underestimated low levels of colonisation in in-
fants where DNA was below the limit of detection. Second,
we identified only one culture-confirmed case of GBS inva-
sive disease. The low number of positive invasive isolates
Table 6 Single variable analysis of infant GBS colonisation dynamics over time compared to birth.
Birth
OR (95% CI)
Day 6 Day 60e89
OR (95% CI) OR (95% CI)
Mother GBS colonised at delivery
Birth season Dry cool 1 0.2 (0.1e0.6) 0.1 (0.0e0.4)
Dry hot 4.6 (2.2e9.7) 1.9 (1.0e4.1) 0.6 (0.2e1.3)
Wet 1.4 (0.7e2.8) 0.7 (0.3e1.5) 0.3 (0.1e0.7)
Living children 0 1 0.5 (0.3e0.9) 0.2 (0.1e0.4)
1e4 0.9 (0.5e1.6) 0.4 (0.2e0.7) 0.1 (0.0e0.3)
5þ 0.9 (0.3e2.6) 0.6 (0.2e1.8) 0.2 (0.0e0.9)
Gestation at birth (wks.) <34 1 0.4 (0.1e1.4) ND
34e37 0.9 (0.3e2.4) 0.3 (0.1e0.9) 0.2 (0.1e0.7)
38þ 0.4 (0.1e1.0) 0.2 (0.1e0.5) 0.0 (0.0e0.1)
Infant weight (kg) 2.5e3 1 0.5 (0.2e1.0) 0.1 (0.0e0.3)
3.1e4.0 1.2 (0.4e3.8) 0.7 (0.3e0.9) 0.1 (0.1e0.3)
>4.0 0.6 (0.1e2.3) 0.3 (0.1e0.7) 0.1 (0.0e0.6)
BM colonised Yes 0.9 (0.5e1.7) 0.4 (0.2e0.8) 0.3 (0.1e0.7)
No 1 0.4 (0.3e0.6) 0.1 (0.1e0.2)
Infant sex Male 1 0.4 (0.3e0.7) 0.1 (0.1e0.3)
Female 0.7 (0.4e1.2) 0.4 (0.2e0.6) 0.1 (0.1e0.3)
Mother not GBS colonised at delivery
Birth season Dry cool 1 1.4 (0.5e4.3) 0.8 (0.2e2.8)
Dry hot 1 1.3 (0.3e5.3) 4.7 (1.7e13.5)
Wet 2.1 (0.8e6.0) 4.1 (1.6e10.5) 0.2 (0.0e1.9)
Living children 0 1 1.8 (0.5e5.7) 1.7 (0.5e5.6)
1e4 1.0 (0.3e2.9) 2.2 (0.8e5.9) 0.7 (0.2e2.3)
5þ 2.0 (0.1e7.1) 1 0.8 (0.1e7.3)
Gestation at birth (wks.) <34 1 3.3 (0.3e34.4) 1
34e37 1.6 (0.2e13.4) 2.5 (0.3e20.6) 1.4 (0.2e13.0)
38þ 1.1 (0.1e9.0) 2.2 (0.3e17.3) 1.3 (0.2e10.8)
Infant weight (kg) 2.5e3.0 1 1.2 (0.4e3.8) 0.6 (0.1e2.3)
3.1e4.0 0.5 (0.2e1.4) 1.2 (0.5e2.9) 0.6 (0.2e1.7)
>4.0 0.9 (0.2e2.3) 1.7 (0.9e4.9) 0.4 (0.3e2.2)
BM colonised Yes 14.2 (4.0e50.8) 6.9 (2.5e19.1) 3.3 (1.2e11.0)
No 1 2.0 (0.9e4.2) 1.0 (0.4e2.5)
Infant sex Male 1 1.4 (0.6e3.1) 0.8 (0.3e2.0)
Female 0.3 (0.1e1.0) 1.1 (0.5e2.5) 0.5 (0.2e1.5)
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may represent an underestimation of the burden of GBS
disease in this population. Several infants died prior to
recruitment or after recruitment but of early onset pneu-
monia without a culture-positive diagnosis and it is
conceivable that they may have succumbed to early onset
GBS disease. There are no other data from the Gambia
regarding the burden of GBS disease. Although we recog-
nize the limitations of its approach, the only other evi-
dence for GBS disease in the Gambia is shown by a
retrospective review of positive cultures from the MRC
hospital over 8 years that identified 17 positive cultures
from infants under 90 days of age which is consistent
with our disease estimate of 1.3/1000 live births.31 Finally,
sampling at 4 h post-birth may indicate contamination
with maternal secretions rather than established colonisa-
tion at birth. However, the fact that few infants lost colo-
nisation at day 6 indicates that colonisation was persistent
over the first week of life.
GBS capsular polysaccharide-protein conjugate vaccines
are being developed, making the findings of our study
important to ensure that appropriate serotypes are
included in candidates that would be relevant to all African
populations. Information about GBS colonisation and fac-
tors affecting acquisition and duration of colonisation will
Maternal colonisation by serotype
Total=237
8.44%  Ia
6.75%  Ib
16.46%  II
10.13%  III
54.85%  V
3.38%  other
Infant colonisation by serotype V2
Total=107
6.54%  Ia
7.48%  Ib
17.76%  II
8.41%  III
58.88%  V
0.93%  other
BM colonisation by serotype V1
Total=60
1.67%  Ia
10.00%  Ib
3.33%  II
15.00%  III
63.33%  V
6.67%  other
BM colonisation by serotype V3
Total=79
3.80%  Ia
5.06%  II
5.06%  III
86.08%  V
Infant colonisation by serotype V1
Total=158
7.59%  Ia
5.06%  Ib
17.09%  II
10.76%  III
56.96%  V
2.53%  other
Infant colonisation by serotype V3
Total=50
20.00%  Ia
10.00%  Ib
24.00%  II
2.00%  III
44.00%  V
BM colonisation by serotype V2
Total=50
4.00%  Ia
6.00%  Ib
10.00%  II
24.00%  III
48.00%  V
8.00%  other
Figure 2 Colonising serotype distribution by isolation site and time point. Maternal rectovaginal colonisation at delivery; breast-
milk and infant colonisation by time point; BMZ breastmilk; IaZ serotype Ia, IbZ serotype Ib, IIZ serotype II, IIIZ serotype III,
V Z serotype V.
292 K. Le Doare et al.
be helpful in considering strategies for reducing the burden
of infant GBS disease worldwide.
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